Exciting Clinical Data Update from Jasper Therapeutics
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company, has shared significant updates regarding their innovative therapy, briquilimab, aimed at treating chronic spontaneous urticaria (CSU). The latest developments emerged from the ongoing BEACON Phase 1b/2a study, where remarkable results were observed in participants receiving different doses of briquilimab. Impressively, 8 out of 9 participants (89%) treated with 240mg and 360mg single doses achieved a complete response.
The impact of briquilimab extends beyond mere numbers. Among the individuals enrolled in the 180mg Q8W open-label extension study, 8 of 11 participants (73%) reported a complete response after 12 weeks. This data adds to the growing body of evidence suggesting the efficacy of briquilimab as a robust treatment option for CSU.
Study Results and Drug Lot Issues
While the data from the 240mg Q8W and 240mg followed by 180mg Q8W cohorts was promising, researchers noted that the results appeared confounded due to complications related to one specific drug product lot. Notably, the ETESIAN study focused on asthma has also been halted because of this inconsistency with drug product supply. Fortunately, there were no serious adverse events reported, indicating that briquilimab remains a safe option for treatment.
Jasper Therapeutics is currently investigating the matter concerning the affected drug product lot. Preliminary findings indicated that the 10 patients who received doses from this lot experienced unexpected drops in mean tryptase levels without any significant impact on Urticaria Activity Score (UAS7). However, two participants from a different lot achieved complete responses, highlighting the importance of the medication’s quality and stability in clinical results.
Next Steps and Patient Transitioning
The company has initiated the process of supplying new drug product to clinical sites, ensuring that the 10 patients previously dosed with the problematic lot transition to a more reliable formulation for their next administration. In line with this, Jasper plans to recruit an additional 10-12 patients across the aforementioned cohorts to reinforce the data set, aiding in the planning of the upcoming Phase 2b CSU study. Anticipated data from these additional participants is expected to be made public in the fourth quarter of 2025, with the Phase 2b study projected to commence in mid-2026.
Management's Vision and Future Directions
Ronald Martell, the President and CEO of Jasper, expressed optimism regarding the progress made with briquilimab. He stated, “The results from the single-dose cohorts show that briquilimab can lead to deep and durable disease control in CSU patients. The efficacy observed in the 180mg Q8W extension study aligns with our vision of providing effective therapies.” Alongside these advancements, the company has made the strategic decision to halt the ETESIAN asthma study to concentrate resources on the development of briquilimab in CSU. Additionally, they are pausing development for severe combined immunodeficiency (SCID) to streamline efforts and reduce operational costs.
Study Design Insights and Efficacy Measurements
The BEACON study is characterized as a randomized, double-blind, placebo-controlled trial, meticulously designed to evaluate the safety and tolerability of multiple ascending doses of briquilimab in adults with moderate to severe CSU, even after using higher dosages of antihistamines. Among its primary endpoints, the trial measures safety while secondary endpoints focus on clinical activity and pharmacokinetics.
The method for gauging clinical efficacy revolves around observing the sum of the Hives Severity Score alongside the daily Itch Severity Score over a week-long period, quantified through the UAS7 scale. Outcomes from recent assessments revealed significant reductions in UAS7 scores across participant groups, showcasing the potential of briquilimab in providing meaningful relief.
Upcoming Conference and Further Information
As a continuation of their commitment to transparency and stakeholder engagement, Jasper will host a conference call and webinar to discuss these findings further. Scheduled for an upcoming date, this session will feature a question and answer segment where management will interact closely with attendees.
In conclusion, Jasper Therapeutics is making strides with briquilimab, aiming to revolutionize treatment for chronic urticaria. Through ongoing studies and adjustments following clinical feedback, the company remains dedicated to improving patient outcomes.
Frequently Asked Questions
What is Briquilimab used for?
Briquilimab is being developed as a treatment for chronic spontaneous urticaria and chronic inducible urticaria, targeting mast cell-driven diseases.
What were the results of the BEACON study?
The BEACON study showed that 89% of participants in the 240mg and 360mg cohorts achieved a complete response, while 73% in the 180mg Q8W extension study did as well.
What issues affected the study's results?
The study faced complications related to one drug product lot, which affected the results for some participants. An investigation is underway to fully understand the implications.
When will further data be available?
Additional data from the extended study is expected in Q4 of 2025, with plans for the Phase 2b study to begin in mid-2026.
How can I learn more about Jasper Therapeutics?
For more information, please visit Jasper Therapeutics’ official website at www.jaspertx.com.
